thalidomide has been researched along with Female Genital Neoplasms in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas." | 9.12 | Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. ( Blank, SV; Christos, P; Fields, AL; Goldberg, GL; Murgo, A; Runowicz, CD; Timmins, P; Wadler, S; Yi-Shin Kuo, D, 2006) |
| "To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas." | 5.12 | Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. ( Blank, SV; Christos, P; Fields, AL; Goldberg, GL; Murgo, A; Runowicz, CD; Timmins, P; Wadler, S; Yi-Shin Kuo, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| WALKER, J | 1 |
| Yi-Shin Kuo, D | 1 |
| Timmins, P | 1 |
| Blank, SV | 1 |
| Fields, AL | 1 |
| Goldberg, GL | 1 |
| Murgo, A | 1 |
| Christos, P | 1 |
| Wadler, S | 1 |
| Runowicz, CD | 1 |
| Chon, HS | 1 |
| Hu, W | 1 |
| Kavanagh, JJ | 1 |
| Ma, WW | 1 |
| Jimeno, A | 1 |
3 reviews available for thalidomide and Female Genital Neoplasms
| Article | Year |
|---|---|
ADVANCES IN OBSTETRICS AND GYNAECOLOGY.
Topics: Anemia; Endocrinology; Erythroblastosis, Fetal; Female; Genital Neoplasms, Female; Gynecology; Hormo | 1963 |
Targeted therapies in gynecologic cancers.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2006 |
Strategies for suppressing angiogenesis in gynecological cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dru | 2007 |
1 trial available for thalidomide and Female Genital Neoplasms
| Article | Year |
|---|---|
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
Topics: Administration, Oral; Carcinosarcoma; Female; Genital Neoplasms, Female; Humans; Neoplasm Recurrence | 2006 |